El tratamiento de la cardiopatía isquémica ha avanzado en paralelo al conocimiento de las bases fisiopatológicas de la enfermedad. La demostración de la trombosis coronaria como causa inmediata del infarto agudo de miocardio, el papel de la activación de la angiotensina en el remodelado miocárdico, la importancia del sistema adrenérgico en la función ventricular y el valor del control de las concentraciones de colesterol han sido los cuatro pilares fundamentales sobre los que se han desarrollado las estrategias terapéuticas que utilizamos en la actualidad. En este artículo se revisan brevemente los fármacos antitrombóticos, los bloqueadores beta, los bloqueadores del sistema renina-angiotensina-aldosterona y las estatinas.
Palabras clave
Inhibidores agregación plaquetaria
Anticoagulantes
Inhibidores angiotensina
Bloqueadores beta
Estatinas
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
ISIS-2 (Second International Study of Infarct survival) Collaborative Group.
Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17.187 cases of suspected acute myocardial infarction: ISIS-2.
Lancet, (1988), 2 pp. 349-360
[2.]
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
BMJ, (2002), 324 pp. 71-86
[3.]
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med. 2001;345:494-502. Fe de erratas en: N Engl J Med. 2001;345:1716 y N Engl J Med. 2001;345: 1506.
[4.]
J.A. Cairns, P. Theroux, H.D. Lewis Jr, M. Ezekowitz, T.W. Meade.
Antithrombotic agents in coronary artery disease.
Chest, (2001), 119 pp. 228S-252S
[5.]
P.M. Ridker, J.E. Manson, J.M. Gaziano, J.E. Buring, C.H. Hennekens.
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.
Ann Intern Med, (1991), 114 pp. 835-839
[6.]
M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. López-Sendón, G. Montalescot, P. Theroux, et al.
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
N Engl J Med, (2005), 352 pp. 1179-1189
[7.]
CAPRIE Steering Committee.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events.
Lancet, (1996), 348 pp. 1329-1339
[8.]
A. Schomig, F.J. Neumann, A. Kastrati, H. Schuhlen, R. Blasini, M. Hadamitzky, et al.
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
N Engl J Med, (1996), 334 pp. 1084-1089
[9.]
G.W. Stone, C.L. Grines, D.A. Cox, E. García, J.E. Tcheng, J.J. Griffin, et al.
Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
N Engl J Med, (2002), 346 pp. 957-966
[10.]
G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, P. Villain, et al.
ADMIRAL Investigators. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
N Engl J Med, (2001), 344 pp. 1895-1903
[11.]
D. Antoniucci, A. Rodriguez, A. Hempel, R. Valenti, A. Migliorini, F. Vigo, et al.
A ramdomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.
J Am Coll Cardiol, (2003), 42 pp. 1879-1885
[12.]
M.L. Simoons.
The Gusto IV-ACS investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
Lancet, (2001), 357 pp. 1915-1924
[13.]
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina.
The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
Circulation, (1998), 97 pp. 2386-2395
[14.]
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.
N Engl J Med, (1998), 338 pp. 1488-1497
[15.]
A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina.
The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.
N Engl J Med, (1998), 338 pp. 1498-1505
[16.]
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
N Engl J Med, (1998), 339 pp. 436-443
[17.]
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41.299 cases of suspected acute myocardial infarction.
Lancet, (1992), 339 pp. 753-770
[18.]
GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12.490 patients with acute myocardial infarction.
Lancet, (1990), 336 pp. 65-71
[19.]
The GUSTO investigators.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
N Engl J Med, (1993), 329 pp. 673-682
[20.]
Assessment of Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators.
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Lancet, (2001), 358 pp. 605-613
[21.]
L. Wallentin, P. Goldstein, P.W. Armstrong, C.B. Granger, A.A. Adgey, H.R. Arntz, et al.
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT- 3 PLUS) randomized trial in acute myocardial infarction.
Circulation, (2003), 108 pp. 135-142
[22.]
W. Klein, A. Buchwald, E.S. Hillis, S. Monrad, G. Sanz, A.G. Graham, et al.
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC).
Circulation, (1997), 96 pp. 61-68
[23.]
E.M. Antman, M. Cohen, D. Radley, C. McCabe, J. Rush, J. Premmereur, et al.
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11BESSENCE meta-analysis.
Circulation, (1999), 100 pp. 1602-1608
[24.]
H. White.
Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial.
Lancet, (2001), 358 pp. 1855-1863
[25.]
ISIS-1 (First International Study of Infarct Survival) collaborative group.
Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1.
Lancet, (1986), II pp. 57-66
[26.]
J. López-Sendón, K. Swedberg, J. McMurray, J. Tamargo, A.P. Maggioni, H. Dargie, et al.
Expert consensus document on beta-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology.
Eur Heart J, (2004), 25 pp. 1341-1362
[27.]
R. Roberts, W.J. Rogers, H.S. Mueller, C.T. Lambrew, D.J. Diver, H.C. Smith, et al.
Immediate versus deferred betablockade follo-wing thrombolytic therapy in patients with acute myocardial infarction (TIMI) IIB study.
Circulation, (1991), 83 pp. 422-437
[28.]
S.J. Kernis, K.J. Harjai, G.W. Stone, L.L. Grines, J.A. Boura, W.W. O’Neill, et al.
Does beta-bloquer therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled analysis from the primary angioplasty in myocardial infarction-2 (PAMI-2), No surgery on-site (noSOS), stent PAMI and Air PAMI trials.
Circulation, (2003), 108 pp. 1237-1246
[29.]
S. Gottlieb, R. McCarter, R. Vogel.
Effect of beta-blockade on mortality among high risk patients after myocardial infarction.
N Engl J Med, (1998), 338 pp. 489-497
[30.]
S. Yusuf, J. Witte, L. Friedman.
Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factor modifications.
JAMA, (1988), 260 pp. 2259-2263
[31.]
S. Yusuf, J. Lessem, P. Jha, E. Lonn.
Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials.
J Hypertens, (1993), 11 pp. S61-S73
[32.]
M.E. Bertrand, M.L. Simoons, K.A. Fox, L.C. Wallentin, C.W. Hamm, E. McFadden, et al.
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology.
Eur Heart J, (2002), 23 pp. 1809-1840
[33.]
N. Freemantle, J. Cleland, P. Young, J. Mason, J. Harrison.
Beta blockade after myocardial infarction. Systematic review and meta regression analysis.
BMJ, (1999), 318 pp. 1730-1737
[34.]
F. Van de Werf, D. Ardissino, A. Betriu, D.V. Cokkinos, E. Falk, K.A. Fox, et al.
Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.
Eur Heart J, (2003), 24 pp. 28-66
[35.]
The beta-blocker pooling project research group.
The beta-blocker pooling project. Subgroup findings from randomized trials in postinfarction patients.
Eur Heart J, (1988), 9 pp. 8-16
[36.]
H.J. Dargie, I. Ford, K.M. Fox.
Total ischaemic burden European trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group.
Eur Heart J, (1996), 17 pp. 104-112
[37.]
N. Rehnqvist, P. Hjemdahl, E. Billing, I. Bjorkander, S.V. Eriksson, L. Forslund, et al.
Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. angina prognosis study in Stockholm.
Cardiología, (1995), 40 pp. S301
[38.]
S. Savonitto, D. Ardissino, K. Egstrup, K. Rasmussen, E.A. Bae, T. Omland, et al.
Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the international multicenter angina exercise (IMAGE) study.
J Am Coll Cardiol, (1996), 27 pp. 311-316
[39.]
S. Yusuf, P. Held, C. Furberg.
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.
Am J Cardiol, (1991), 67 pp. 1295-1297
[40.]
R.S. Gibson, W.E. Boden, P. Theroux, H.D. Strauss, C.M. Pratt, M. Gheorghiade, et al.
Diltiazem and reinfarction in patients with non Q-wave myocardial infarction: results of a double-blind, randomized, multi-center trial.
N Engl J Med, (1986), 315 pp. 423
[41.]
W.E. Boden, W.H. van Gilst, R.G. Scheldewaert, I.R. Starkey, M.F. Carlier, D.G. Julian, et al.
Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis.
Lancet, (2000), 355 pp. 1751-1756
[42.]
N.L.R.G. Smith, G.E. Reiberge, B.M. Psaty, S.R. Heckbert, D.S. Siscovick, J.L. Ritchie, et al.
Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina.
J Am Coll Cardiol, (1998), 32 pp. 1305-1311
[43.]
J.T.J. Lubsen, J.G. Tijssen.
Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT).
Am J Cardiol, (1987), 60 pp. 18A-25A
[44.]
P.Y.S. Held, C.D. Furberg.
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.
BMJ, (1989), 299 pp. 1187-1192
[45.]
E. Braunwald.
Mechanism of action of calcium-channel-blocking agents.
N Engl J Med, (1982), 307 pp. 1618-1627
[46.]
C.D. Furberg, B.M. Psaty, J.V. Meyer.
Nifedipine: dose-related increase in mortality in patients with coronary heart disease.
Circulation, (1995), 92 pp. 1326-1331
[47.]
J.M. Detry, P. Sellier, S. Pennaforte, D. Cokkinos, H. Dargie, P. Mathes.
Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.
Br J Clin Pharmacol, (1994), 37 pp. 279-288
[48.]
S. Dalla-Volta, G. Maraglino, P. Della-Valentina, P. Viena, A. Desideri.
Comparison of trimetazidine with nifedipine in effort angina: a double blind cross over study.
Cardiovasc Drugs Ther, (1990), 4 pp. 853-860
[49.]
S. Levy, The group of South of France Investigators.
Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease.
Am J Cardiol, (1995), 76 pp. B12-B16
[50.]
M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr, T.E. Cuddy, et al.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
N Engl J Med, (1992), 327 pp. 669-677
[51.]
The AIRE Study Investigators.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.
Lancet, (1993), 342 pp. 821-828
[52.]
L. Kober, C. Torp-Pedersen, J.E. Carlsen, H. Bagger, P. Eliasen, K. Lyngborg, et al.
A clinical trial of the ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. TRACE Study Group.
N Engl J Med, (1995), 333 pp. 1670-1676
[53.]
K. Swedberg, P. Held, J. Kjekshus, K. Rasmussen, L. Ryden, H. Wedel.
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the CONSENSUS II.
N Engl J Med, (1992), 327 pp. 678-684
[54.]
GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.
Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico.
Lancet, (1994), 343 pp. 1115-1122
[55.]
E. Ambrosini, C. Borghi, B. Magnani.
The effect of the ACE inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.
N Engl J Med, (1995), 332 pp. 80-85
[56.]
ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
Lancet, (1995), 345 pp. 669-685
[57.]
CCS-1 Collaborative Group.
Oral captopril versus placebo among 14,062 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group.
Chin Med J (Engl), (1997), 110 pp. 834-838
[58.]
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais.
Effects of an ACE inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med, (2000), 342 pp. 145-153
[59.]
K.M. Fox, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study).
Lancet, (2003), 362 pp. 782-788
[60.]
K. Dickstein, J. Kjekshus, OPTIMAAL Steering Committee of the OPTIMAAL Study Group.
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
Lancet, (2002), 360 pp. 752-760
[61.]
M.A. Pfeffer, J.J. McMurray, E.J. Velázquez, J.L. Rouleau, L. Kober, A.P. Maggioni, et al.
Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular disfunción, or both.
N Engl J Med, (2003), 349 pp. 1893-1906
[62.]
B. Pitt, H. White, J. Nicolau, F. Martinez, M. Gheorghiade, M. Aschermann, et al.
EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
J Am Coll Cardiol, (2005), 46 pp. 425-431
[63.]
P.M. Ridker, C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, et al.
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE ITTIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy.
N Engl J Med, (2005), 352 pp. 20-28
[64.]
S. Tsimikas, J.L. Witztum, E.R. Miller, W.J. Sasiela, M. Szarek, A.G. Olsson, et al.
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Circulation, (2004), 110 pp. 1406-1412
[65.]
J.A. De Lemos, M.A. Blazing, S.D. Wiviott, E.F. Lewis, K.A. Fox, H.D. White, et al.
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
JAMA, (2004), 292 pp. 1307-1316
[66.]
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, (1994), 344 pp. 1383-1389
[67.]
M.A. Pfeffer, F.M. Sacks, L.A. Moye, L. Brown, J.L. Rouleau, L.H. Hartley, et al.
Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators.
Am J Cardiol, (1995), 76 pp. C98-C106
Copyright ©
2006. Sociedad Española de Cardiología